Nelarabine is indicated for the treatment of patients with T-cell acute lymphoblastic leukaemia (T-ALL) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.
For this indication, competent medicine agencies globally authorize below treatments:
1,500 - 1,500 mg per m² of body surface area (BSA)
From 1,500 To 1,500 mg per m² of body surface area (BSA) once every 2 day(s) for 5 day(s)
The recommended dose of nelarabine for adults and adolescents aged 16 years and older is 1,500 mg/m² administered intravenously over two hours on days 1, 3 and 5 and repeated every 21 days.
Nelarabine must be discontinued at the first sign of neurological events of National Cancer Institute Common Terminology Criteria Adverse Event (NCI CTCAE) grade 2 or greater. Delaying subsequent dosing is an option for other toxicities, including haematological toxicity.
It should be administered intravenously as a two-hour infusion.